Difference in sarcopenia prevalence and associated factors according to 2010 and 2018 European consensus (EWGSOP) in elderly patients with type 2 diabetes mellitus

Freitas, Mauren Minuzzo de; Oliveira, Vanessa Lopes Preto de; Grassi, Thaiciane; Valduga, Kamila; Miller, Maria Elisa Peinado; Schuchmann, Renata Asnis; Souza, Karen Liz Araújo; Azevedo, Mirela Jobim de; Viana, Luciana Verçoza; Paula, Tatiana Pedroso de

doi:10.1016/j.exger.2020.110835

Cited by 52 publications

(43 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[26]. In geriatric patients, the literature is conflicting showing higher [27][28][29] or equal [30,31] rates of sarcopenia with the 2010 compared to the 2019 definition. The predictive utility for complications seems to be different for the 2010 and 2019 definition-in chronic obstructive pulmonary disease both definitions performed well, whereas in the UK biobank cohort the 2010 definition was superior in predicting poorer health outcome.…”

Section: Discussionmentioning

confidence: 99%

Sarcopenia and Liver Cirrhosis—Comparison of the European Working Group on Sarcopenia Criteria 2010 and 2019

et al. 2020

View full text Add to dashboard Cite

The European Working group on Sarcopenia in Older People recently updated the diagnostic criteria for sarcopenia. It is yet unclear how these modified criteria influence the rate of diagnosis in high risk populations, such as liver cirrhosis. We therefore assessed if the new diagnostic criteria for sarcopenia impacts on sarcopenia prevalence in liver cirrhosis. Within two years 114 cirrhotic patients were prospectively enrolled in the study. Sarcopenia was determined by muscle strength (handgrip strength), muscle mass (lumbal muscle index) and muscle performance (gait speed). Using the 2019 definition, the rate of pre-sarcopenia was significantly lower (30.7% versus 3.5%) due to the different starting points (2010 muscle mass, 2019 muscle strength) and cut-off values (muscle strength). The change in diagnostic criteria for sarcopenia drastically influences the rate of pre-sarcopenia diagnosis in cirrhotics. To evaluate, which diagnostic criteria should be chosen to diagnose sarcopenia in liver cirrhosis patients, prospective studies are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Sarcopenia and Liver Cirrhosis—Comparison of the European Working Group on Sarcopenia Criteria 2010 and 2019

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Several studies comparing EWGSOP1 and 2 have been published. Some studies show good agreement [ 9 , 11 – 13 ], but others find poor agreement between the two criteria [ 8 , 10 , 14 – 21 ]. Populations, settings, techniques, testing procedures, and cut-offs have varied, leading to differences in the prevalence of sarcopenia, making comparisons between studies difficult [ 8 , 11 – 22 ].…”

Section: Introductionmentioning

confidence: 99%

Comparison of the 2010 and 2019 diagnostic criteria for sarcopenia by the European Working Group on Sarcopenia in Older People (EWGSOP) in two cohorts of Swedish older adults

et al. 2021

View full text Add to dashboard Cite

Background The operational definition of sarcopenia has been updated (EWGSOP2) and apply different cut-off points compared to previous criteria (EWGSOP1). Therefore, we aim to compare the sarcopenia prevalence and the association with mortality and dependence in activities of daily living using the 2010 (EWGSOP1 and 2019 (EWGSOP2 operational definition, applying cut-offs at two levels using T-scores. Methods Two birth cohorts, 70 and 85-years-old (n = 884 and n = 157, respectively), were assessed cross-sectionally (57% women). Low grip strength, low muscle mass and slow gait speed were defined below − 2.0 and − 2.5 SD from a young reference population (T-score). Muscle mass was defined as appendicular lean soft tissue index by DXA. The EWGSOP1 and EWGSOP2 were applied and compared with McNemar tests and Cohen’s kappa. All-cause mortality was analyzed with the Cox-proportional hazard model. Results Sarcopenia prevalence was 1.4–7.8% in 70-year-olds and 42–62% in 85 years-old’s, depending on diagnostic criteria. Overall, the prevalence of sarcopenia was 0.9–1.0 percentage points lower using the EWGSOP2 compared to EWGSOP1 when applying uniform T-score cut-offs (P < 0.005). The prevalence was doubled (15.0 vs. 7.5%) using the − 2.0 vs. -2.5 T-scores with EWGSOP2 in the whole sample. The increase in prevalence when changing the cut-offs was 5.7% (P < 0.001) in the 70-year-olds and 17.8% (P < 0.001) in the 85-year-olds (EWGSP2). Sarcopenia with cut-offs at − 2.5 T-score was associated with increased mortality (hazard ratio 2.4–2.8, P < 0.05) but not at T-score − 2.0. Conclusions The prevalence of sarcopenia was higher in 85-year-olds compared to 70-year-olds. Overall, the differences between the EWGSOP1 and EWGSOP2 classifications are small. Meaningful differences between EWGSOP1 and 2 in the 85-year-olds could not be ruled out. Prevalence was more dependent on cut-offs than on the operational definition.

show abstract

“…In the present study, the prevalence of sarcopenia was 12.5% among 1,137 patients, and the patients with sarcopenia had higher HbA1c than the patients without sarcopenia. In contrast, another report showed the prevalence of 18.7% among 267 Japanese patients with type 2 diabetes, whereas a study among Chinese and European patients with type 2 diabetes reported the prevalence of sarcopenia to be 28.8% 22 and 21% 27 , respectively. HbA1c level did not differ between those with and without sarcopenia 12,27 .…”

Section: Discussionmentioning

confidence: 87%

“…In contrast, another report showed the prevalence of 18.7% among 267 Japanese patients with type 2 diabetes, whereas a study among Chinese and European patients with type 2 diabetes reported the prevalence of sarcopenia to be 28.8% 22 and 21% 27 , respectively. HbA1c level did not differ between those with and without sarcopenia 12,27 . The patients with sarcopenia in the present study were at relatively advanced ages compared with these studies 12,22,28 , and were overweight, had weak grip strength, low usual gait speed and low SMI compared with the other Japanese study 12 .…”

Section: Discussionmentioning

confidence: 87%

Significance of body mass index for diagnosing sarcopenia is equivalent to slow gait speed in Japanese individuals with type 2 diabetes: Cross‐sectional study using outpatient clinical data

Nakanishi

Iwamoto

Shinohara

et al. 2020

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction This study examined the association between body mass index (BMI) and the risk of sarcopenia in Japanese type 2 diabetes patients. Materials and Methods Patients with type 2 diabetes who visited an outpatient clinic comprised the study’s participants. Sarcopenia was defined using the definition of the Asian Working Group for Sarcopenia 2014. The area under the curve was examined for the presence of sarcopenia based on the receiver operating characteristic curve of BMI. Results Among 1,137 patients, 210 were diagnosed with low grip strength, 78 with slow gait speed, 444 with low muscle mass and 142 with sarcopenia. The optimal cut‐off point of BMI level for risk of sarcopenia was 24.4 kg/m2 (area under the curve 0.729, 95% confidence interval 0.688–0.770, sensitivity 0.587, specificity 0.789). Furthermore, the receiver operating characteristic curve of BMI for sarcopenia did not significantly differ (P = 0.09) from that of gait speed, an established marker of sarcopenia. In both the male and female groups, there was no difference between the receiver operating characteristic curves of BMI and gait speed for sarcopenia. (P = 0.23 and P = 0.40, respectively). Conclusions These results suggest that a BMI <24 kg/m2 among Japanese patients with type 2 diabetes could increase their risk of sarcopenia, the extent of which is equivalent to the risk for sarcopenia from slow gait speed in this study. Further prospective investigation, however, is required.

show abstract

Difference in sarcopenia prevalence and associated factors according to 2010 and 2018 European consensus (EWGSOP) in elderly patients with type 2 diabetes mellitus

Cited by 52 publications

References 37 publications

Sarcopenia and Liver Cirrhosis—Comparison of the European Working Group on Sarcopenia Criteria 2010 and 2019

Sarcopenia and Liver Cirrhosis—Comparison of the European Working Group on Sarcopenia Criteria 2010 and 2019

Comparison of the 2010 and 2019 diagnostic criteria for sarcopenia by the European Working Group on Sarcopenia in Older People (EWGSOP) in two cohorts of Swedish older adults

Significance of body mass index for diagnosing sarcopenia is equivalent to slow gait speed in Japanese individuals with type 2 diabetes: Cross‐sectional study using outpatient clinical data

Contact Info

Product

Resources

About